

**Avastin (bevacizumab)
 Mvasi (bevacizumab-awwb)
 Zirabev (bevacizumab-bvzr)
 Vegzelma (bevacizumab-adcd)
 Alymsys (bevacizumab-maly)
 Effective 01/01/2024**

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Bevacizumab is a vascular Endothelial Growth Factor (VEGF) inhibitor indicated for multiple cancers.

Note: Avastin for ocular diagnoses are found on a separate criteria document

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Avastin, Mvasi, Zirabev, Vegzelma, or Alymsys excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when the following have been met:

1. Colorectal cancer (CRC)
 - a. The member has a diagnosis of colorectal cancer, including small bowel adenocarcinoma, appendiceal carcinoma, and anal adenocarcinoma
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
2. Non-small cell lung cancer (NSCLC)
 - a. The member has a diagnosis of recurrent, advanced, or metastatic non-squamous NSCLC
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
3. CNS cancer
 - a. The member has ONE of the following diagnosis:
 - i. Glioblastoma
 - ii. Intracranial and spinal ependymoma (excludes sub-ependymoma)

- iii. Anaplastic gliomas
 - iv. Low-grade (WHO Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma
 - v. Medulloblastoma
 - vi. Primary central nervous system lymphoma
 - vii. Meningiomas
 - viii. Limited and extensive brain metastases
 - ix. Leptomeningeal metastases
 - x. Metastatic spine tumors
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 4. Ovarian cancer/Fallopian tube cancer/Primary peritoneal cancer
 - a. Member has a diagnosis of the following types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer:
 - i. Epithelial ovarian cancer, including: Carcinosarcoma (malignant mixed Müllerian tumors)
 - ii. Clear cell carcinoma
 - iii. Mucinous carcinoma
 - iv. Grade 1 endometrioid carcinoma
 - v. Low-grade serous carcinoma
 - vi. Borderline epithelial tumors (low malignant potential) with invasive implants
 - vii. Malignant sex cord-stromal tumors
 - viii. Fallopian tube cancer
 - ix. Primary peritoneal cancer
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 5. Uterine/Endometrial cancer
 - a. The member has a diagnosis of progressive, advanced, or recurrent uterine cancer or endometrial cancer
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 6. Cervical/Vaginal cancer
 - a. The member has a diagnosis of persistent, recurrent, or metastatic cervical or vaginal cancer
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 7. Breast cancer
 - a. The member has a diagnosis of breast cancer
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 8. Renal cell carcinoma
 - a. The member has a diagnosis of relapsed or metastatic renal cell carcinoma
 - b. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 9. Soft tissue sarcoma
 - a. The member has a diagnosis of soft tissue sarcoma
 - a. For **Avastin, AlymSYS, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 10. Angiosarcoma
 - a. The member has a diagnosis of angiosarcoma, as single agent therapy.



- b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 11. Solitary fibrous tumor/hemangiopericytoma
 - a. The member has a diagnosis of solitary fibrous tumor or hemangiopericytoma, in combination with temozolomide
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 12. Malignant pleural mesothelioma
 - a. The member has a diagnosis of malignant pleural mesothelioma, in combination with pemetrexed and either cisplatin or carboplatin, followed by single agent maintenance therapy
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 13. AIDS-related Kaposi sarcoma
 - a. The member has a diagnosis of AIDS-related Kaposi sarcoma
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 14. Vulvar cancer
 - a. The member has a diagnosis of unresectable locally advanced, recurrent, or metastatic vulvar cancer.
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 15. Peritoneal mesothelioma
 - a. The member has a diagnosis of peritoneal mesothelioma
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 16. Tunica vaginalis testis mesothelioma
 - a. The member has a diagnosis of tunica vaginalis testis mesothelioma.
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi
- 17. Hepatocellular carcinoma
 - a. The member has a diagnosis of hepatocellular carcinoma, in combination with atezolizumab
 - b. For **Avastin, Alymsys, Vegzelma and Zirabev**: The member has had an inadequate response or intolerance to Mvasi

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member's condition.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months

References

1. Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech; May 2020
2. Mvasi (bevacizumab-awwb) [prescribing information]. Thousand Oaks, CA: Amgen Inc; June 2019
3. Zirabev (bevacizumab-bvzr) [prescribing information]. New York, NY: Pfizer Labs; January 2020
4. Ray-Coquard I, Pautier P, Pignata S, et al; PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361
5. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894-1905. doi:10.1056/NEJMoa1915745



6. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [published correction appears in *Lancet*. 2016;387(10026): e24.]. *Lancet*. 2016;387(10026):1405-1414
7. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
8. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. *Cancer*. 2011;117(21):4939-4947
9. Gupta S, Parsa VB, Heilbrun LK, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. *Anticancer Drugs*. 2011;22(8):794-800
10. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. *Ann Oncol*. 2013;24(1):257-263
11. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol*. 2013;31(24):3004-3011
12. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*. 2014;370(8):734-743

Review History

11/18/2020- Updated: moved Avastin to non-preferred, moved Mvasi and Zirabev to preferred for non-ocular diagnoses; moved to MB only; P+T reviewed

11/17/2021 – Updated and Reviewed at Nov P&T; Mvasi moved to preferred agent; Avastin and Zirabev moved to nonpreferred agent. Effective 01/01/2022.

10/11/2023 – Updated and Reviewed for Oct P&T; Added Vegzelma and Alymsys to criteria as non-preferred agents. Effective 1/1/2024

